November 25, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: | PMV Pharmaceuticals, Inc. | |||
Registration Statement on Form S-3 Filed November 20, 2024 | ||||
File No. 333-283349 | ||||
Acceleration Request | ||||
Requested Date: | Wednesday, November 27, 2024 | |||
Requested Time: | 4:30 P.M. Eastern Time |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, PMV Pharmaceuticals, Inc. (the Company) hereby requests that the above-referenced Registration Statement on Form S-3 (the Registration Statement) be declared effective at the Requested Date and Requested Time set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Megan J. Baier at (212) 497-7736.
[Signature page follows]
Securities and Exchange Commission
November 25, 2024
Page 2
Sincerely, |
PMV PHARMACEUTICALS, INC. |
/s/ Michael Carulli |
Michael Carulli |
Chief Financial Officer |
cc: | Kenneth A. Clark, Tony Jeffries, and Megan J. Baier, Wilson Sonsini Goodrich & Rosati, P.C. |